

LIST OF TABLES

| | | Page |
|------------|---|------|
| Table I | Number of patients whose data were used for analyses in different chapters of Report No. 14 | 11 |
| Table II | Distribution of prognostic stages in patients diagnosed in 2018 | 11 |
| Table 1.1 | Family history of breast cancer at diagnosis (N=19,723) | 21 |
| Table 1.2 | Personal history of other tumours at diagnosis (N=19,723) | 21 |
| Table 1.3 | Origins of malignant tumours reported by patients (N=354) | 22 |
| Table 1.4 | History of benign breast disease at diagnosis (N=19,723) | 22 |
| Table 1.5 | Menarche, menopause and reproductive history at diagnosis | 23 |
| Table 1.6 | Number of live births reported by patients (N=14,905) | 23 |
| Table 1.7 | Use of hormonal contraceptives at diagnosis (N=19,723) | 24 |
| Table 1.8 | Use of hormone replacement therapy at diagnosis (N=10,460) | 24 |
| Table 1.9 | Ten most common risk factors for breast cancer in patient cohort (N=19,723) | 25 |
| Table 1.10 | Breast screening habits by age group | 26 |
| Table 1.11 | Breast screening habits by education level | 27 |
| Table 1.12 | Breast screening habits by monthly household income (HK\$) | 28 |
| Table 1.13 | Breast screening habits by district of residence | 29 |
| Table 2.1 | Methods of first breast cancer detection by type of medical service users (N=18,927) | 34 |
| Table 2.2 | Methods of first breast cancer detection by type of cancer (N=18,642) | 35 |
| Table 2.3 | Methods of first breast cancer detection by cancer stage (N=18,142) | 35 |
| Table 2.4 | Time interval between onset of symptoms and first medical consultation for patients who self-detected their cancer by type of medical service users (N=4,557) | 36 |
| Table 2.5 | Cancer stage at diagnosis among self-detected patients by time interval between onset of symptoms and first medical consultation (N=3,709) | 37 |
| Table 2.6 | Number of patients and breast cancer cases in the patient cohort (N=20,006) | 37 |
| Table 2.7 | Sensitivity and diagnostic results of breast imaging tests (N=20,006) | 38 |
| Table 2.8 | Mammographic findings of patients diagnosed through mammography (N=14,403) | 39 |
| Table 2.9 | Mammographic density of breasts of patients diagnosed through mammogram by age group (N=9,774) | 39 |
| Table 2.10 | Sensitivity and diagnostic results of breast tissue biopsies (N=20,006) | 40 |
| Table 2.11 | Method of cancer staging among invasive breast cancer patients (N=7,799) | 41 |
| Table 2.12 | Histological type of invasive breast cancer (N=16,697) | 44 |
| Table 2.13 | Grading, multifocality and multicentricity of invasive breast cancer (N=16,697) | 44 |
| Table 2 14 | Riological characteristics of invasive breast cancer (N=16,697) | 45 |



| | | Page |
|------------|--|------|
| Table 2.15 | Biological subtypes of invasive tumours by cancer stage (N=15,688) | 46 |
| Table 2.16 | Histological type, grading, multifocality and multicentricity of in situ breast cancer (N=2,514) | 47 |
| Table 2.17 | Biological characteristics of in situ breast cancer (N=2,514) | 47 |
| Table 2.18 | Number of treatment modalities by cancer stage (N=19,150) | 48 |
| Table 2.19 | Use of surgery for patients with invasive or in situ cancer | 49 |
| Table 2.20 | Coverage of regional lymph nodes by adjuvant locoregional radiotherapy (N=7,416) | 53 |
| Table 2.21 | Use of chemotherapy by age group and cancer stage at diagnosis (N=16,235) | 54 |
| Table 2.22 | Follow-up of patients (N=18,014) | 63 |
| Table 2.23 | Recurrence pattern of patients (N=17,402) | 63 |
| Table 2.24 | Locoregional recurrence by type of surgery received and cancer stage at diagnosis | 64 |
| Table 2.25 | Sites involved in locoregional recurrence (N=781) | 64 |
| Table 2.26 | Sites involved in distant recurrence (N=905) | 65 |
| Table 2.27 | Time for organ specific metastasis and distribution of the biological subtypes of patients | 65 |
| Table 2.28 | Locoregional and distant recurrence among invasive breast cancer patients by cancer stage (N=14,745) | 66 |
| Table 2.29 | Characteristics of breast cancer-specific deaths (N=990) | 66 |
| Table 3.1 | Psychosocial impact of breast cancer | 72 |
| Table 3.2 | Psychosocial adjustments and coping strategies for survivorship | 73 |
| Table 4.1 | Ten most common risk factors for breast cancer in patient cohort (N=1,682) | 77 |
| Table 4.2 | Breast screening habits | 78 |
| Table 4.3 | Biological subtypes of invasive tumours by cancer stage (N=759) | 80 |
| Table 4.4 | Number of treatment modalities by cancer stage (N=985) | 81 |



LIST OF FIGURES

| | | rage |
|-------------|--|------|
| Figure I | Distribution of year of diagnosis of HKBCR participants | 7 |
| Figure 1.1 | Distribution of age at diagnosis (N=19,723) | 17 |
| Figure 1.2 | Occupation of patient cohort (N=19,723) | 17 |
| Figure 1.3 | Education level of patient cohort (N=19,723) | 18 |
| Figure 1.4 | Monthly household income (HK\$) of patient cohort (N=10,811) | 18 |
| Figure 1.5 | District of residence of patient cohort (N=19,723) | 18 |
| Figure 1.6 | Bra band size of patient cohort (N=15,272) | 19 |
| Figure 1.7 | Bra cup size of patient cohort (N=12,844) | 19 |
| Figure 1.8 | Dietary habits at diagnosis (N=19,723) | 20 |
| Figure 1.9 | Exercise habits at diagnosis (N=19,723) | 20 |
| Figure 1.10 | Stress level at diagnosis (N=19,723) | 20 |
| Figure 1.11 | Body mass index at diagnosis (N=19,723) | 21 |
| Figure 1.12 | Distribution of risk factors among patients at diagnosis (N=19,723) | 25 |
| Figure 2.1 | Methods of first breast cancer detection in the patient cohort (N=18,927) | 34 |
| Figure 2.2 | Major presenting symptoms of self-detected breast cancer in the patient cohort (N=15,604) | 35 |
| Figure 2.3 | Time interval between onset of symptoms and first medical consultation for patients who self-detected their cancer (N=4,225) | 36 |
| Figure 2.4 | Locations of malignant tumour on breasts within the patient cohort (N=20,006) | 38 |
| Figure 2.5 | Mammographic density of breasts of patients diagnosed through mammogram (N=9,945) | 39 |
| Figure 2.6 | Use of PET scan among patients who had cancer staging by cancer stage (N=7,799) | 41 |
| Figure 2.7 | Cancer stage at diagnosis (N=20,006) | 42 |
| Figure 2.8 | Distribution of tumour size (cm) of invasive breast cancer (N=14,463) | 42 |
| Figure 2.9 | Number of positive axillary lymph nodes among patients with invasive breast cancer (N=14,965) | 43 |
| Figure 2.10 | Distribution of tumour size (cm) of in situ breast cancer (N=2,076) | 43 |
| Figure 2.11 | Type of breast surgery by age group (N=19,189) | 50 |
| Figure 2.12 | Type of breast surgery by invasive tumour size (cm) (N=14,438) | 50 |
| Figure 2.13 | Type of breast surgery by cancer stage (N=18,904) | 50 |
| Figure 2.14 | Type of breast surgery by type of medical service (N=18,750) | 50 |
| Figure 2.15 | Type of nodal surgery by clinical nodal status (N=18,296) | 51 |
| Figure 2.16 | Type of nodal surgery for invasive cancer by cancer stage (N=16,110) | 51 |
| Figure 2.17 | Distribution of tumour size (cm) in invasive cancer with negative or positive nodal status $(N=14,382)$ | 51 |
| Figure 2.18 | Number of positive nodes by type of nodal surgery (N=16,225) | 52 |
| Figure 2.19 | Use of radiotherapy among patients who underwent breast-conserving surgery by cancer stage (N=6,952) | 53 |
| Figure 2.20 | Use of radiotherapy among patients who underwent mastectomy by cancer stage (N=11,626) | 53 |
| Figure 2.21 | Use of chemotherapy by cancer stage (N=16,471) | 54 |
| | | |



| | | Page |
|-------------|--|------|
| Figure 2.22 | Type of first generation chemotherapy regimens (non-HER2) used in neoadjuvant setting (N=161) | 55 |
| Figure 2.23 | Type of second generation chemotherapy regimens (non-HER2) used in neoadjuvant setting (N=137) | 55 |
| Figure 2.24 | Type of third generation chemotherapy regimens (non-HER2) used in neoadjuvant setting (N=525) | 55 |
| Figure 2.25 | Type of HER2 regimens used in neoadjuvant setting (N=434) | 55 |
| Figure 2.26 | Type of chemotherapy regimens used by biological subtype in neoadjuvant setting (N=1,226) | 56 |
| Figure 2.27 | Type of first generation chemotherapy regimens (non-HER2) used in adjuvant setting (N=1,671) | 57 |
| Figure 2.28 | Type of second generation chemotherapy regimens (non-HER2) used in adjuvant setting (N=2,694) | 57 |
| Figure 2.29 | Type of third generation chemotherapy regimens (non-HER2) used in adjuvant setting (N=2,761) | 57 |
| Figure 2.30 | Type of HER2 regimens used in adjuvant setting (N=875) | 57 |
| Figure 2.31 | Type of chemotherapy regimens used by biological subtype in adjuvant setting (N=8,321) | 58 |
| Figure 2.32 | Type of chemotherapy regimens used by cancer stage in adjuvant setting (N=8,457) | 59 |
| Figure 2.33 | Type of chemotherapy regimens used by biological subtype in palliative setting (N=240) | 60 |
| Figure 2.34 | Use of endocrine therapy by cancer stage (N=19,086) | 61 |
| Figure 2.35 | Forms of endocrine therapy by age group (N=12,289) | 61 |
| Figure 2.36 | Type of targeted therapy drugs used (N=2,864) | 62 |
| Figure 2.37 | Use of anti-HER2 targeted therapy in HER2 positive patients by cancer stage (N=3,477) | 62 |
| Figure 2.38 | Type of complementary and alternative therapies used (N=7,155) | 63 |
| Figure 3.1 | Level of physical discomfort after surgery (N=17,696) | 69 |
| Figure 3.2 | Level of physical discomfort by type of surgery (N=17,645) | 69 |
| Figure 3.3 | Level of physical discomfort after radiotherapy (N=10,169) | 69 |
| Figure 3.4 | Level of physical discomfort after radiotherapy by irradiated regions (N=6,775) | 70 |
| Figure 3.5 | Level of physical discomfort after chemotherapy (N=10,367) | 70 |
| Figure 3.6 | Level of physical discomfort after endocrine therapy (N=11,234) | 70 |
| Figure 3.7 | Level of physical discomfort after targeted therapy (N=2,306) | 71 |
| Figure 3.8 | Level of physical discomfort after complementary and alternative therapies (N=6,930) | 71 |
| Figure 3.9 | Change in outlook on life by age group (N=17,150) | 72 |
| Figure 3.10 | Change in self-image by age group (N=17,147) | 73 |
| Figure 3.11 | Level of worry about recurrence by age group (N=17,151) | 73 |
| Figure 4.1 | Distribution of age at diagnosis (N=1,682) | 77 |
| Figure 4.2 | Education level of patient cohort (N=1,682) | 77 |
| Figure 4.3 | Distribution of risk factors among patients at diagnosis (N=1,682) | 77 |
| Figure 4.4 | Methods of first breast cancer detection in the patient cohort (N=1,032) | 78 |
| Figure 4.5 | Time interval between onset of symptoms and first medical consultation for patients who self-detected their cancer (N=388) | 78 |
| Figure 4.6 | Cancer stage at diagnosis (N=1,052) | 79 |
| Figure 4.7 | Distribution of tumour size (cm) of invasive breast cancer (N=666) | 79 |
| Figure 4.8 | Number of positive axillary lymph nodes among patients with invasive breast cancer (N=683) | 79 |
| Figure 4.9 | Distribution of tumour size (cm) of in situ breast cancer (N=177) | 80 |